Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.03 USD
Change Today -0.002 / -7.31%
Volume 345.0K
SCRC On Other Exchanges
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

scripsamerica inc (SCRC) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/29/15 - $0.22
52 Week Low
08/4/15 - $0.02
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SCRIPSAMERICA INC (SCRC)

Related News

No related news articles were found.

scripsamerica inc (SCRC) Related Businessweek News

No Related Businessweek News Found

scripsamerica inc (SCRC) Details

ScripsAmerica, Inc. primarily develops, markets, and distributes branded over the counter (OTC) pharmaceutical products in the United States and China. It primarily focuses on the marketing, sale, and distribution of RapiMed pediatric acetaminophen products. The company was founded in 2008 and is based in Tysons Corner, Virginia.

2 Employees
Last Reported Date: 04/22/14
Founded in 2008

scripsamerica inc (SCRC) Top Compensated Officers

Chief Financial Officer and Principal Account...
Total Annual Compensation: $178.0K
Compensation as of Fiscal Year 2013.

scripsamerica inc (SCRC) Key Developments

ScripsAmerica Mulls Acquisitions

ScripsAmerica, Inc. (OTCPK:SCRC) is looking for acquisitions. The company indicated that the primary focus of its growth strategy will be in the specialty pharmacy market as it plans to continue adding new states to its distribution network and evaluating strategic acquisitions of new pharmacies.

ScripsAmerica, Inc. Hires James F. Buchanan as Medical Director

ScripsAmerica, Inc. announced that it has hired James F. Buchanan, Pharm.D. as a drug safety consultant who will serve as the company's Medical Director, overseeing all medical and insurance compliance operations. Dr. James Buchanan, PharmD has over 24 years of drug safety industry experience and currently serves as Senior Vice President of Pharmacovigilance and Risk Management at BioSoteria, Inc. He began his industry career at Genentech, working for nine years in the areas of medical information and drug safety in the clinical development department before moving to Gilead Sciences to establish the BioSoteria's drug safety department and serving as Associate Director then Director of Drug Safety.

ScripsAmerica, Inc. Announces Auditor Changes

ScripsAmerica announced that its Board approved the engagement of KMJ Corbin & Company LLP as the company's independent registered public accounting firm effective immediately, and dismissed Friedman LLP as the company's independent registered public accounting firm.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCRC:US $0.03 USD -0.002

SCRC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Dr Reddy's Laboratories Ltd 4,053 INR -156.35
Glenmark Pharmaceuticals Ltd 1,026 INR -35.80
Henry Schein Inc $133.27 USD -1.88
Jubilant Life Sciences Ltd 332.25 INR -14.55
Mylan NV $48.05 USD +0.63
View Industry Companies

Industry Analysis


Industry Average

Valuation SCRC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCRIPSAMERICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at